



PRESS RELEASE

Kurma Partners is pursuing the implementation of its investment strategy in innovation to create Biotech companies

ImCheck Therapeutics raises €20 million

Paris, May 3, 2017 - Kurma Partners, a European venture capital company specialized in Life Sciences, announced today the closing of the first (Series A) €20 million financing round of ImCheck Therapeutics, a company created according to Kurma's investment model in innovation.

ImCheck Therapeutics: an emerging leader in immuno-oncology created following Kurma Partners' model

Created in 2015 as a partnership between Boehringer Ingelheim Venture Fund and Kurma Partners, ImCheck Therapeutics is a spin-off from the Cancer Research Center of Marseille (CRCM). The company specializes in developing new therapeutic approaches in immuno-oncology based on the work conducted by Daniel Olive, an internationally renowned expert who has been head of the CRCM's "*Immunity and Cancer*" team for more than 20 years.

In a highly competitive sector as immuno-oncology, ImCheck Therapeutics has benefited from the support and expertise of Kurma Partners' team ever since it was created. Today it has raised €20 million from a prestigious group of investors for the development of its therapeutic programs, with the aim of beginning clinical trials by 2019.

ImCheck Therapeutics is also announcing the appointment as its CEO of Pierre d'Epenoux, also Theravectys Group's former.

Kurma Partners' model: foster innovation by setting up academic, industrial and financial partnerships

Driven by an increasing need for innovation, the French healthcare sector faces today a major issue: the need to raise funds faster and in a way that first with the constant evolution of the sector.

Kurma Partners' model aims to bring the key players in the healthcare industry together to create new businesses by harnessing its network of academic, business and industry partners. With Kurma Biofund II, Kurma Partners has been involved in the creation of four Biotech companies, including ImCheck Therapeutics.

"Immuno-oncology is a highly competitive sector, where it is getting harder to identify and nurture the development of innovations with genuine therapeutic potential", commented Rémi Droller, Managing Partner of Kurma Partners. "Thanks to our unique investment strategy and our network of partners, we are able to give companies, like ImCheck Therapeutics, access to technological and financial resources that will allow them to see the development of their products through from the research phase to market launch."

About Kurma Partners - www.kurmapartners.com

Founded in July 2009, Kurma Partners is a key European venture capital player in the Life Sciences sector, notably through its Kurma Biofund I fund, Kurma Biofund II fund and Kurma Diagnostics acceleration fund. Managing funds totalling over €250 million, Kurma's investment strategy is based both on a selection of the best European companies and on the creation of a portfolio of "proprietary" companies in which Kurma intervenes from their very creation.

Media contact:

NewCap

Nicolas Merigeau

+33 (0)1 44 71 94 98

nmerigeau@newcap.fr